The new SEC rules limit preferential treatment in Side Letters (Section 8.3). Historically, institutional LPs negotiated preferential terms via Side Letters, so I want to know if they’re now pushing back or finding workarounds. I also want to understand how biotech/health funds are handling regulatory carve-outs that LPs previously included in Side Letters.